Yahoo Finance 
Oxford And AstraZeneca Covid-19 Vaccine Trial Row Explained
Oxford University and AstraZeneca have acknowledged a manufacturing error meant some trial participants received only a partial dose of their experimental Covid-19 vaccine.
The announcement has raised questions about why researchers did not mention the error when they claimed the jab was “highly effective” just days ago.
It has also raised some concerns about the part of the study which showed a 90% success rate. Oxford and AstraZeneca have since addressed these issues and explained the next steps for the jab, to ensure its safety and effectiveness.
On Thursday night, researchers announced they planned to conduct an additional global trial to assess the vaccine to validate this.
AstraZeneca CEO Pascal Soriot told Bloomberg News: “Now that we’ve found what looks like a better efficacy, we have to validate this, so we need to do an additional study.”
Soriot said he did not expect the additional trial to hold up regulatory approvals in the UK and European Union – but it is thought the concerns over the trial could hold up approval in the US.
Here is what we know:
The study
On Monday, Oxford and AstraZeneca announced preliminary results from trials showed an average efficacy of 70% – a figure reached by pooling the results from two different dosing regimens.
One month apart, one set of volunteers received two identical doses while the other received a half-dose, and then a full dose. In the first group, the efficacy was 62%. In the second, 90%.
The results were hailed a success, but it has since been revealed that some volunteers were only given a half dose because some of the vials did not have the right concentration of vaccine.
Mene Pangalos, R&D lead at AstraZeneca, admitted to this dosing error to Reuters on Monday.
The manufacturing error was only caught when some of the people in the study did not show the usual adverse effects. Oxford has said it discussed the problem with regulators and completed the late-stage trial with two groups.
The second...
